DRI Healthcare Trust (TSE:DHT.UN – Get Free Report) has earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is C$18.25.
A number of research firms recently issued reports on DHT.UN. Raymond James cut DRI Healthcare Trust from a “strong-buy” rating to an “outperform” rating and set a C$24.00 price objective for the company. in a report on Tuesday, July 9th. National Bankshares lowered their target price on shares of DRI Healthcare Trust from C$23.50 to C$17.50 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Stifel Nicolaus downgraded shares of DRI Healthcare Trust from a “buy” rating to a “hold” rating and reduced their price target for the stock from C$22.00 to C$15.00 in a research note on Tuesday, July 9th. Truist Financial lowered their price objective on shares of DRI Healthcare Trust from C$17.00 to C$14.00 in a research report on Thursday, July 25th. Finally, Scotiabank lifted their price target on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th.
Check Out Our Latest Stock Report on DRI Healthcare Trust
DRI Healthcare Trust Trading Up 33.5 %
DRI Healthcare Trust Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 18th. Shareholders of record on Friday, October 18th will be issued a dividend of $0.085 per share. The ex-dividend date is Friday, September 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.41%. DRI Healthcare Trust’s dividend payout ratio is currently -920.00%.
DRI Healthcare Trust Company Profile
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Featured Articles
- Five stocks we like better than DRI Healthcare Trust
- About the Markup Calculator
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- How to Use the MarketBeat Stock Screener
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Best Stocks Under $5.00
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for DRI Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DRI Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.